The use of health technology assessment (HTA) is growing steadily in Europe, and the U.S. government has recently announced $1.1 billion in funding for comparative effectiveness research (CER) as part of its planned overhaul of the U.S. healthcare system. Payers in all markets will increasingly compare new drugs with established therapies and offer the most favorable pricing and reimbursement terms only to drugs that are deemed innovative.
Questions Answered in This Report:
HTA has become a major focus of attention in healthcare systems around the world in recent years. - What are the key elements of HTA? - What approaches have the authorities in leading pharmaceutical markets taken to the use of HTA?
European governments have used various forms of HTA for many years. - How do HTA strategies vary from one European country to another? - What common trends can be observed in Europe?
The United States has been much slower than other mature pharmaceutical markets to embrace HTA. - Which U.S. organizations have practiced HTA in the past? - What action has the U.S. government recently taken to stimulate greater use of CER in the United States?
Scope:
- Increasing focus on HTA: definitions of HTA; role of health economic evaluation; strategies in major markets. - Use of HTA in leading markets: France; Germany; Italy; Spain; United Kingdom; United States; international collaborations. - Outlook and implications for the pharmaceutical industry: European industry’s key principles for HTA; challenges presented by the adoption of CER in the United States; key message to payers.
